Related Experiment Video
Updated: Aug 4, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.8K
Current concepts and novel targets for antiplatelet therapy
Meinrad Gawaz1, Tobias Geisler2, Oliver Borst2
1Department of Cardiology and Angiology, Eberhard Karls University of Tübingen, Tübingen, Germany. meinrad.gawaz@med.uni-tuebingen.de.
Nature Reviews. Cardiology
|April 4, 2023
Summary
Platelets are key in blood clotting and atherosclerosis. New antiplatelet drugs may reduce bleeding risk and offer better cardiovascular disease treatment strategies.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Platelets play a vital role in hemostasis and atherothrombosis.
- Current antiplatelet therapies reduce thrombo-ischaemic events but increase bleeding risk.
- Platelets also influence inflammatory and microcirculatory pathways.
Purpose of the Study:
- To review the role of platelets in myocardial ischemia, vascular inflammation, and atherosclerosis.
- To highlight current antiplatelet therapy concepts and their impact on patient care.
- To discuss novel antiplatelet targets and compounds in development.
Main Methods:
- Literature review of pathophysiological roles.
- Analysis of current clinical antiplatelet therapy concepts.
- Overview of preclinical antiplatelet drug development.
Main Results:
- Platelet hyper-reactivity contributes to myocardial ischemia and atherosclerotic progression.
- Existing therapies improve outcomes but carry bleeding risks.
- Novel antiplatelet agents show promise for improved safety and efficacy.
Conclusions:
- Platelet modulation is crucial for managing cardiovascular diseases.
- New antiplatelet therapies may offer improved risk-benefit profiles.
- Targeting platelets presents new avenues for cardiovascular disease treatment.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
574
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
574
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
783
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
783
01:27Peripheral Artery Disease III: Interprofessional Care
15
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
15
01:26Targets for Drug Action: Overview
6.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.6K
01:29Venous Thrombosis III: Interprofessional Care
13
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
13